The group will use state-of-the-art molecular technologies to investigate various eye diseases and seek knowledge that can provide novel and improved treatments for patients.

We will follow the vision of OUS: "Our research shall provide knowledge - for the benefit of the patients" and the goal: "Research shall generate new knowledge that will lead to better diagnostics, treatment, and prevention of disease."

The research shall generate new knowledge that will lead to better diagnostics, treatment, and prevention of eye diseases. We will use new molecular technologies to achieve these goals.

The research group investigates eye diseases using state-of-the-art molecular technologies, with a particular focus on uveal melanoma. The aim is to increase the understanding of disease mechanisms, identify novel prognostic and diagnostic biomarkers, and contribute to the development of more targeted and effective treatments for patients.

The group’s projects include studies of genetic and epigenetic alterations, the use of CRISPR technology, and analyses of tumor biology through single cell and spatial transcriptomics. The research also explores biomarkers such as circulating tumor DNA (ctDNA) and extracellular vesicles. In addition, the group works for improved diagnostics and conducts research in regenerative medicine and tissue engineering for the treatment of various eye diseases.

Overall, the research group integrates molecular biology, bioinformatics, and clinical research to improve the diagnosis, prognostication, and treatment of eye diseases.